Oculis Holding AG (NASDAQ:OCSAW) Sees Significant Growth in Short Interest

Oculis Holding AG (NASDAQ:OCSAW) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 10,370 shares, an increase of 203.9% from the July 15th total of 3,412 shares. Based on an average daily trading volume, of 3,070 shares, the days-to-cover ratio is currently 3.4 days.

Oculis Stock Performance

Shares of NASDAQ:OCSAW remained flat at $5.00 during mid-day trading on Friday. Oculis has a 1-year low of $3.63 and a 1-year high of $22.64. The business’s 50-day moving average is $4.47 and its 200 day moving average is $12.00.

About Oculis

Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.

Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.